Pharma News

“It is a piece of misinformation that subsequent waves of the COVID-19 pandemic are going to cause severe illness in children. There is no data - either from India or globally - to show that children will be seriously infected in subsequent waves.” This was informed by Director, All India Institute of Medical Sciences (AIIMS) Delhi, Dr. Randeep Guleria, during a media briefing on COVID-19, held at National Media Centre, PIB Delhi today.

Type 1 diabetes, which arises when the pancreas doesn’t create enough insulin to control levels of glucose in the blood, is a disease that currently has no cure and is difficult for most patients to manage. Scientists at the Salk Institute are developing a promising approach for treating it: using stem cells to create insulin-producing cells (called beta cells) that could replace nonfunctional pancreatic cells.

New research identified a novel interaction between the SARS-CoV-2 spike protein and the galectin-3-binding protein (LGALS3BP) which could be a new therapeutic anti-viral target. The research also found the presence of detectable viral RNA in blood in COVID-19 patients is a strong predictor of mortality.

A new AI-driven platform will now help early intervention through rapid screening of COVID 19 with the help of Chest X-ray interpretation over WhatsApp for doctors who have access to X-ray machines. The solution called XraySetu can work with low-resolution images sent via mobiles, is quick and easy to use, and can facilitate detection in rural areas.

Haffkine Biopharma to produce 22.8 crore doses per annum of Covaxin under technology transfer arrangement with Bharat Biotech With the aim of vaccinating the entire eligible population at the earliest, domestic vaccine production is being steadily ramped up in the country with help from the Centre. As part of this initiative, three public enterprises are being supported by  the Department of Biotechnology under Atmanirbhar Bharat 3.0  Mission Covid Suraksha. 

Association of advanced pharmacy practitioners (AAPP) shows strong oppose  against Mankind Pharmaceuticals for using compounder term and notify them to use term as Pharmacist. AAPP has sent a notice to Mankind Pharma to withdraw the term Compounder from the poster circulated by them and to recirculate it by using the appropriate term as Pharmacist.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

Global pharma major, Lupin Limited (Lupin), announced the launch of the authorized generic version of Brovana® (arformoterol tartrate) Inhalation Solution 15 mcg/2 mL, unit-dose vials, of Sunovion Pharmaceuticals Inc.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

Boehringer Ingelheim and Zealand Pharma A/S announced that the US Food and Drug Administration has granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis . The Fast Track Designation facilitates the development and expedites the review of new therapies to treat serious conditions and fill an unmet medical need. BI 456906 is currently being evaluated in a Phase II study in adults with NASH and liver fibrosis (F2/F3) with and without diabetes.